Physician profile
Mitchell C Bober
NPI 1902805013
$4,181.55
in general payments reported to CMS, 2019-2025
31 companies · $46.03 in 2025
The $46.03 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $173 · 2021: $553 · 2022: $557 · 2023: $1,005 · 2024: $1,162 · 2025: $46.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,256.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $589.14 | 2021-2024 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $478.46 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $442.12 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $248.52 | 2019-2024 | Zoryve |
| Amgen INC. | $210.38 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $162.54 | 2021-2025 | |
| Lilly USA, LLC | $77.48 | 2023 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $69.79 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $68.01 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $67.79 | 2021 | |
| Philips North America LLC | $52.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $44.16 | 2019-2023 | Dificid |
| Astellas Pharma US INC | $42.01 | 2019-2023 | Veozah |
| Dexcom, INC. | $36.83 | 2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $35.86 | 2022 | |
| Allergan, INC. | $31.64 | 2020 | |
| Xeris Pharmaceuticals, INC. | $31.27 | 2024 | Keveyis |
| Sanofi-Aventis U.S. LLC | $29.57 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.86 | 2019 | |
| Medtronic, INC. | $24.84 | 2023 | Inpen Smart Insulin Delivery System |
| Inspire Medical Systems, INC. | $20.61 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $20.20 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.14 | 2023 | Quviviq |
| Amarin Pharma, INC. | $15.25 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.99 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.64 | 2024 | Voquezna |
| Smith+Nephew, INC. | $12.91 | 2021 | |
| Almatica Pharma LLC | $12.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Bober listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.